CanSense
Sketty, United Kingdom
CanSense is developing a fast, inexpensive and scalable test for the early diagnosis of bowel cancer using artificial intelligence-based modelling (AI). The test is a potential game changer in the approach to bowel cancer diagnosis and screening. It is focused on patient acceptability and reduced mortality via early stage diagnosis. It has the additional benefit of reducing the demands on more invasive colonoscopy diagnosis and reducing the financial burden on the healthcare provider.
Company Info
- Founded
- 2018
- Website
- cansenseltd.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of CanSense?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.